1094209-33-2Relevant articles and documents
N-Arylsulfonyl-α-amino carboxamides are potent and selective inhibitors of the chemokine receptor CCR10 that show efficacy in the murine DNFB model of contact hypersensitivity
Abeywardane, Asitha,Caviness, Gary,Choi, Younggi,Cogan, Derek,Gao, Amy,Goldberg, Daniel,Heim-Riether, Alexander,Jeanfavre, Debra,Klein, Elliott,Kowalski, Jennifer A.,Mao, Wang,Miller, Craig,Moss, Neil,Ramsden, Philip,Raymond, Ernest,Skow, Donna,Smith-Keenan, Lana,Snow, Roger J.,Wu, Frank,Wu, Jiang-Ping,Yu, Yang
, p. 5277 - 5283 (2016/11/11)
Compound 1 ((4-amino-3,5-dichlorophenyl)-1-(4-methylpiperidin-1-yl)-4-(2-nitroimidazol-1-yl)-1-oxobutane-2-sulfonamido) was discovered to be a 690 nM antagonist of human CCR10 Ca2+flux. Optimization delivered (2R)-4-(2-cyanopyrrol-1-yl)-S-(1H-indol-4-yl)-1-(4-methylpiperidin-1-yl)-1-oxobutane-2-sulfonamido (eut-22) that is 300 fold more potent a CCR10 antagonist than 1 and eliminates potential toxicity, mutagenicity, and drug–drug-interaction liabilities often associated with nitroaryls and anilines. eut-22 is highly selective over other GPCR's, including a number of other chemokine receptors. Finally, eut-22 is efficacious in the murine DNFB model of contact hypersensitivity. The efficacy of this compound provides further evidence for the role of CCR10 in dermatological inflammatory conditions.
2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10
-
Page/Page column 126-127, (2009/11/29)
This invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein R1, R2, R4. Ar and Het are as defined herein. The invention also relates to methods of using the compound of for
